PDCD1 and neoplasm: Targeted inhibition of CD39 not only enhances the cytotoxicity of CD8+ tumor-infiltrating lymphocytes (TILs) but also promotes B cell infiltration, thereby amplifying the anti-tumor immune effect of PD-1 blockade (99).